Management of hyperprolactinemic infertility

Middle East Fertility Society Journal

Volumn 17, Issue 2, 2012, Pages 63-69

  Crosignani, P G ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Anovulation; Defective luteal phase; Hyperprolactinemia; Pituitary adenoma; Prolactinoma

Indexed keywords

ANTIEMETIC AGENT; ANTIESTROGEN; BROMOCRIPTINE; CABERGOLINE; CLOMIFENE CITRATE; DOPAMINE RECEPTOR BLOCKING AGENT; ESTROGEN DERIVATIVE; FOLLITROPIN; GONADORELIN; HUMAN MENOPAUSAL GONADOTROPIN; LUTEINIZING HORMONE; NARCOTIC ANALGESIC AGENT; PROLACTIN; QUINAGOLIDE; TRICYCLIC ANTIDEPRESSANT AGENT; VERAPAMIL;

AMENORRHEA; ANOVULATION; BEDTIME DOSAGE; DIZZINESS; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; FEMALE INFERTILITY; HUMAN; HYPERPROLACTINEMIA; HYPOPHYSIS ADENOMA; INFERTILITY; LUTEAL PHASE; MENSTRUAL IRREGULARITY; NAUSEA; OLIGOMENORRHEA; ORTHOSTATIC HYPOTENSION; OVARY POLYCYSTIC DISEASE; OVULATION INDUCTION; PROLACTIN BLOOD LEVEL; PROLACTIN RELEASE; PROLACTINOMA; REVIEW; VALVULAR HEART DISEASE;

EID: 84862892800     PISSN: 11105690     EISSN: 20903251     Source Type: Journal    
DOI: 10.1016/j.mefs.2012.04.003     Document Type: Review

References (46)

1. J.R. Davis Prolactin and reproductive medicine Cure Opin Obstet Gynecol 16 2004 331 337
2. V.K.B. Prabhakar, and J.R.E. Davis Hyperprolactinemia Best Practice & Res Clin Obstet Gynaecol 22 2008 341 353
3. T.H. Kruger, B. Leeners, E. Naegeli, S. Schmidlin, M. Schedlowski, U. Hartmann, and M. Egli Prolactin secretory rhythm in women: immediate and long-term alterations after sexual contact Hum Reprod 27 4 2012 1139 1143
4. A. Milewicz Prolactin levels in the polycystic ovary syndrome J Reprod Med 29 1984 193 196
5. M.E. Molitch Disorders of prolactin secretion Endocrinol Metab Clin North Am 30 2001 585 610
6. P.G. Crosignani, M. Meschia, F. Bruschi, and F. Parazzini Sustained prolactin release associated with precocious ovarian failure Gynecol Obstet Invest 39 1995 63 64
7. A. Bayrak, P. Saadat, E. Mor, L. Chong, R.J. Paulson, and R.Z. Sokol Pituitary imaging is indicated for the evaluation of hyperprolactinemia Fertil Steril 84 2005 181 185
8. A.V. Sluijmer, and R.E. Lappöhn Clinical history and outcome of 59 patients with idiopathic hyperprolactinemia Fertil Steril 58 1992 72 77
9. S. Melmed, F.F. Casanueva, A.R. Hoffman, D.L. Kleinberg, V.M. Montori, J.A. Schlechte, and J.A.H. Wass Clinical Practice Guideline: Diagnosis and Treatment of Hyperprolactinemia: An Endocrine Society Clinical Practice Guideline JCEM 96 2011 273 288
10. D-Y. Lee, Y-K. Oh, B-K. Yoon, and D.S. Choi Prevalence of hyperprolactinemia in adolescents and young women with menstruation-related problems Am J Obstet Gynecol 206 2012 213.e1-5
11. I. Souter, L.M. Baltagi, T.L. Toth, and J.C. Petrozza Prevalence of hyperprolactinemia and abnormal magnetic resonance imaging findings in a population with infertility Fertil Steril 94 2010 1159 1162
12. G.S. Dizerega, and G.T. Ross Luteal phase dysfunction Clin Obstet Gynecol 8 1981 733 751
13. A. Shibli-Rahhal, and J. Schlechte Hyperprolactinemia and infertility Endocrinol Metab Clin N Am 40 2011 837 846
14. J. Gibney, T.P. Smith, and T.J. McKenna The impact on clinical practice of routine screening for macroprolactin J Clin Endocrinol Metab 90 2005 3927 3932
15. P.G. Crosignani, A.M. Mattei, C. Scarduelli, V. Cavioni, and P. Boracchi Is pregnancy the best treatment for hyperprolactinemia? Hum Reprod 4 1989 910 912
16. P.G. Crosignani, C. Scarduelli, G. Brambilla, V. Cavioni, and C. Ferrari Spontaneous pregnancies in hyperprolactinemic women Gynecol Obstet Invest 19 1985 17 20
17. A.I. Levey, S.M. Hersch, and D.B. Rye Localization of D1 and D2 dopamine receptors in brain with subtype-specific antibodies Proc Natl Acad Sci USA 90 1993 8861 8865
18. N. Ben-Jonathan, and R. Hnasko Dopamine as a prolactin (PRL) inhibitor Endocr Rev 22 2001 724 763
19. C. Weil The safety of bromocriptine in hyperprolactinaemic female infertility: a literature review Curr Med Res Opin 10 1986 172 195
20. Y.Z. Diamant, S. Yarkoni, and S. Evron Combined clomiphene-bromocriptine treatment in anovulatory, oligomenorrheic and hyperprolactinemic women resistant to separate clomiphene or bromocriptine regimens Infertility 3 1980 11 16
21. I. Pellegrini, R. Rasolonjanahary, and G. Gunz Resistance to bromocriptine in prolactinomas J Clin Endocrinol Metab 69 1989 500 509
22. B.M. Biller, M.E. Molitch, and M.L. Vance Treatment of prolactinsecreting macroadenomas with the once-weekly dopamine agonist cabergoline J Clin Endocrinol Metab 81 1996 2338 2343
23. J. Verhelst, R. Abs, and D. Maiter Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients J Clin Endocrinol Metab 84 1999 2518 2522
24. G. Stalldecker, M.S. Mallea-Gil, M. Guitelman, A. Alfieri, M.C. Ballarino, L. Boero, A. Chervin, K. Danilowicz, S. Diez, P. Fainstein-Day, N. García-Basavilbaso, M. Glerean, V. Gollan, D. Katz, M.G. Loto, M. Manavela, A.S. Rogozinski, M. Servidio, and N.M. Vitale Effects of cabergoline on pregnancy and embryo-fetal development: retrospective study on 103 pregnancies and a review of the literature Pituitary 13 4 2010 345 350
25. A. Colao, A. Di Sarno, and M.L. Landi Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients J Clin Endocrinol Metab 85 2000 2247 2252
26. F. Bogazzi, S. Buralli, L. Manetti, V. Raffaelli, T. Cigni, M. Lombardi, F. Boresi, S. Taddei, A. Salvetti, and E. Martino Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia Int J Clin Pract 62 2008 1864 1869
27. E. Valassi, A. Klibanski, and B.M. Biller Potential cardiac valve effects of dopamine agonists in hyperprolactinemia J Clin Endocrinol Metab 95 3 2010 1025 1033
28. S. Bhattacharya, A.H. Schapira, D.P. Mikhailidis, and J. Davar Drug-induced fibrotic valvular heart disease Lancet 374 2009 577 585
29. A.J. Claxton, J. Cramer, and C. Pierce A systematic review of the associations between dose regimens and medication compliance Clin Ther 23 2001 1296 1310
30. J. Webster A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation Drug Safety 14 1996 228 238
31. S.E. Sauder, M. Frager, G.D. Case, R.P. Kelch, and J.C. Marshall Abnormal patterns of pulsatile luteinizing hormone secretion in women with hyperprolactinemia and amenorrhea: responses to bromocriptine J Clin Endocrinol Metab 59 5 1984 941 948
32. P. Krupp, and C. Monka Bromocriptine in pregnancy: safety aspects Klin Wochenschr 65 17 1987 823 827
33. M.D. Bronstein Prolactinomas and pregnancy Pituitary 8 2005 31 38
34. M.E. Molitch Pituitary disorders during pregnancy Endocrinol Metab Clin North Am 35 2006 99 116 vi
35. M.P. Gillam, M.E. Molitch, G. Lombardi, and A. Colao Advances in the treatment of prolactinomas Endocr Rev 27 2006 485 534
36. T. Bergh, S.J. Nillius, and P. Enoksson Bromocriptine-induced regression of a suprasellar extending prolactinoma during pregnancy J Endocrinol Invest 7 1984 133 136
37. P.G. Crosignani, C. Ferrari, and A.M. Mattei Visual field defects and reduced visual acuity during pregnancy in two patients with prolactinoma: rapid regression of symptoms under bromocriptine Case reports. Br J Obstet Gynaecol 91 1984 821 823
38. S.L. Tan, and H.S. Jacobs Rapid regression through bromocriptine therapy of a suprasellar extending prolactinoma during pregnancy Int J Gynaecol Obstet 24 1986 209 215
39. W.J. Jeffcoate, N. Pound, N.D. Sturrock, and J. Lambourne Longterm follow-up of patients with hyperprolactinaemia Clin Endocrinol (Oxf) 45 1996 299 303
40. P.G. Crosignani Current treatment issues in female hyperprolactinemia Eur J Obstet Gynecol Reprod Biol 125 2006 152 164
41. A. Czeizel, R. Kiss, K. Racz, K. Mohori, and E. Glaz Case-control cytogenetic study in offspring of mothers treated with bromocriptine during early pregnancy Mutat Res 210 1989 23 27
42. E. Ciccarelli, S. Grottoli, and P. Razzore Long-term treatment with cabergoline, a new long-lasting ergoline derivate, in idiopathic or tumorous hyperprolactinaemia and outcome of drug-induced pregnancy J Endocrinol Invest 20 1997 547 551
43. J.W. van't Verlaat, and R.J. Croughs Withdrawal of bromocriptine after longterm therapy for macroprolactinomas; effect on plasma prolactin and tumour size Clin Endocrinol (Oxford) 34 1991 175 178
44. V. Rohmer, E. Freneau, I. Morange, and C. Simonetta Efficacy of quinagolide in resistance to dopamine agonists: results of a multicenter study. Club de l'Hypophyse Ann Endocrinol (Paris) 61 2000 411 417
45. C. Ferrari, G. Piscitelli, and P.G. Crosignani Cabergoline: a new drug for the treatment of hyperprolactinaemia Hum Reprod 10 1995 1647 1652
46. A. Raappana, J. Koivukangas, T. Ebeling, and T. Pirila Incidence of pituitary adenomas in Northern Finland in 1992-2007 J Clin Endocrinol Metab 95 2010 4268 4275